8-K: Tivic Health Reports Q3 2024 Results, Highlights Vagus Nerve Stimulation Progress

Tivic Health announced its third quarter 2024 financial results, showcasing progress in supply chain improvements and the development of its vagus nerve stimulation technology.

Summary

• Tivic Health reported a net revenue of $126,000 for the third quarter of 2024 and $600,000 for the first nine months of 2024.
• This represents a 27% decrease in revenue compared to the first nine months of 2023, primarily due to a 36% decrease in unit sales, partially offset by a 13% increase in average sales price per unit.
• The company's cost of sales decreased by 34% compared to the first nine months of 2023.
• Gross profit for the first nine months of 2024 was $241,000, down from $282,000 in 2023.
• Total operating expenses decreased by $1.9 million year-to-date compared to the same period in 2023.
• The net loss for the first nine months of 2024 was $4.2 million, an improvement of $1.8 million compared to the same period in 2023.
• Cash and cash equivalents totaled $2.2 million as of September 30, 2024, down from $3.4 million at the end of 2023.
• The company raised $775,000 through sales of common stock in October and November 2024.
• Tivic Health is focusing on developing a non-invasive vagus nerve stimulation system, with a Phase 1 trial showing clinically meaningful changes.
• The company has engaged a growth consulting firm to prioritize high-value use cases for the vagus nerve stimulation program, identifying multi-billion dollar market opportunities.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in supply chain and clinical trials, the financial results show a decline in revenue and a net loss. The company is also facing risks related to future funding and regulatory approvals.

Positives

• The company successfully redesigned its supply chain, leading to a significant increase in gross margin for the ClearUP product line.
• Clinical trials of the non-invasive vagus nerve stimulation system have shown promising results.
• Tivic Health has identified substantial market opportunities for its vagus nerve stimulation technology.
• Operating expenses have been significantly reduced, improving the company's financial position.
• The net loss has decreased year-over-year, indicating progress towards profitability.

Negatives

• Revenue decreased by 27% in the first nine months of 2024 compared to the same period in 2023.
• Unit sales decreased by 36% in the first nine months of 2024 compared to the same period in 2023.
• Gross profit decreased in the first nine months of 2024 compared to the same period in 2023.
• Cash and cash equivalents have decreased from $3.4 million at the end of 2023 to $2.2 million as of September 30, 2024.

Risks

• The company faces risks related to the future development and commercialization of its vagus nerve stimulation treatment.
• There are risks associated with obtaining regulatory approval for clinical products.
• The company's ability to raise additional capital on favorable terms is uncertain.
• Supply chain constraints and macroeconomic factors, including inflation, could impact the business.
• The company's ability to maintain its Nasdaq listing is a risk.

Future Outlook

Tivic Health expects to reach a significant inflection point in the business in the next twelve months as they build out their VNS medical device program and are prioritizing high value use cases based on the needs of patients, providers and payers.

Management Comments

• This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value.
• The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line.
• The second leg, and most important element of our strategy, is our development of a non-invasive vagus nerve stimulation system that has the potential to catalyze Tivic's long-term value.
• We expect to reach a significant inflection point in the business in the next twelve months as we build out our VNS medical device program.

Industry Context

Tivic Health is operating in the growing bioelectronic medicine sector, which focuses on using devices to treat medical conditions. The company's focus on non-invasive vagus nerve stimulation aligns with the trend towards less invasive and drug-free therapeutic solutions.

Comparison to Industry Standards

• Tivic Health's revenue of $600,000 for the first nine months of 2024 is relatively low compared to established medical device companies, such as Medtronic or Boston Scientific, which report billions in revenue.
• The company's focus on non-invasive vagus nerve stimulation is similar to other companies in the bioelectronic medicine space, such as ElectroCore, which also develops devices for nerve stimulation.
• The 70% gross margin achieved after the supply chain redesign is a positive sign, but it is important to compare this to the gross margins of other medical device companies, which can vary widely depending on the product and market.
• The reduction in operating expenses is a positive step, but the company still needs to demonstrate a path to profitability, which is a common challenge for early-stage medical device companies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the net loss, but encouraged by the progress in the vagus nerve stimulation program.
• Employees may be impacted by the company's financial performance and strategic shifts.
• Customers may benefit from the improved ClearUP product line and the potential for new vagus nerve stimulation treatments.
• Suppliers may be affected by the company's supply chain redesign.
• Creditors may be concerned about the company's financial position and ability to repay debts.

Next Steps

• The company will continue to develop its non-invasive vagus nerve stimulation system.
• Tivic Health will work with a growth consulting firm to prioritize high-value use cases for the vagus nerve stimulation program.
• The company will continue to optimize the device parameters for the vagus nerve stimulation system.
• Management will host a conference call to discuss the third quarter results and provide a business update.

Key Dates

Keywords

vagus nerve stimulation, bioelectronic medicine, ClearUP, supply chain, clinical trial, financial results, gross margin, operating expenses, net loss, revenue